Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

The nonprofit says its pipeline offers more affordable and accessible therapeutics, including point-of-care CAR-T cell therapy for leukemia and lymphoma.

The firm enrolled the first patient at Florida's BayCare Morton Plant Hospital, and the study procedure went according to protocol, per an investigator.

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

DCx will gain rights to technology, targets, and preclinical programs from Repare along with lab space and staff in Montreal.

The companies will analyze RNA sequencing data from Scipher to identify biomarkers for patient stratification and drug development.

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.